Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer-Reference-Cited by-同舟云学术

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

Published:2023-10 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Stockhammer Paul,Grant Michael,Wurtz Anna,Foggetti Giorgia,Expósito Francisco,Gu Jianlei,Zhao Hongyu,Choi Jungmin,Chung Sangyun,Li Fangyong,Walther Zenta,Dietz Julia,Duffield Emily,Gettinger Scott,Politi Katerina,Goldberg Sarah B.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

2. Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC);O’Leary;Pharmaceuticals (Basel),2020

3. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer;Sequist;J Clin Oncol,2007

4. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depiction of the Genetic Alterations and Molecular Landscapes of Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis;Cancers;2024-08-25

2. Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status;BMC Pulmonary Medicine;2024-08-24

3. Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer;Molecular Carcinogenesis;2024-06-11

4. Influence of TP53 mutation on efficacy and survival in advanced EGFR‐mutant non‐small cell lung cancer patients treated with third‐generation EGFR tyrosine kinase inhibitors;MedComm;2024-06

5. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations;Clinical Cancer Research;2024-04-17